Tuesday, 13 November 2012

Μεταστατικός Καρκίνος Παχέος Εντέρου Βιβλιογραφία


1. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg.  2004; 239:818–825; discussion 825–827.
2. Adam R., Delvart V., Pascal G., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg.  2004; 240,644–657.
3. Adam R., Aloia T., Levi F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol. 2007; 25:4593–4602.
4. Adam R., de Haas R.J., Wicherts D.A., et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J. Clin. Oncol. 2008; 26,3672–3680.
5. Adam R., Wicherts D.A., de Haas R.J., et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009; 27:1829–1835.
6. Adam R., Bhangui P., Poston G., et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg. 2010; 252:774–787.
7. D'Alessandro A.M., Kalayoglu M., Sollinger H.W., et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation. 1991; 51:157–163.
8. D'Angelica M., Kornprat P., Gonen M., et al. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol. 2007; 14:759–765.
9. DeAngelis R.A., Markiewski M.M., Taub R., et al. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology. 2005; 42:1148–1157.
10. Aloia T., Sebagh M., Plasse M., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006; 24:4983–4990.
11. Altendorf-Hofmann A., Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg. Oncol. Clin. N. Am. 2003; 12,165–192.
12. Auer R.C., White R.R.,Kemeny N.E., et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer. 2010; 116:1502–1509.
13. Aussilhou B., Dokmak S., Faivre S., et al. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol. 2009;16:1553–1559.
14. El-Badry A.M., Breitenstein S., Jochum W., et al. Assessment of hepatic steatosis by expert pathologists: the end of a goldstandard. Ann Surg. 2009;250:691–697.
15. Barnett K.T., Malafa M.P. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer. 2001; 30:147–160.
16. Belghiti J., Hiramatsu K., Benoist S., et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg. 2000; 191:38–46.
17. Benoist S., Brouquet A., Penna C., et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006; 24:3939–3945.
18. Boige V., Malka D., Elias D., et al. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol. 2008;15:219–226.
19. Bokemeyer C., Bondarenko I. ,Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with andwithout cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;,27:663–671.
20. Breitenstein S., DeOliveira M.L., Raptis D.A., et al. Novel and simple preoperative score predicting complications following liver resection in non-cirrhotic patients. Ann Surg. 2010 ; 252:726–34.
21. Brouquet A.,Benoist S., Julie C., et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery. 2009;145:362–371.
22. Capussotti L., Vigano L., Ferrero A. et al. Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann. Surg. Oncol. 2007;14,1143–1150.
23. Carpizo D.R., D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol. 2009; 10,801–809.
24. Carpizo D.R., Are C., Jarnagin W. et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann. Surg. Oncol. 2009; 16,2138–2146.
25. Cejas P., Lopez-Gomex M., Aguayo C. et al. KRAS mutation in primary colorectal cancer tumors and related metastases: A poten tial role in predicition of lung metastasis. PLoS ONE4,E1899, 2009.
26. Chen M.L., Fang C.H., Liang L.S., et al. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. Surg Oncol. 2010; 19:38–45.
27. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002; 235:759–766.
28. Chun Y.S., Laurent A., Maru D., Vauthey J.N. Management of chemotherpy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol. 2009; 10,278–286.
29. Clavien P.A., Selzner N., Morse M., et al. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery. 2002; 131:433–442.
30. Clavien P.A., Petrowsky H., DeOliveira M.L., et al. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med. 2007; 356:1545–1559.
31. Clavien P.A., Oberkofler C.E., Raptis D.A., et al. What is critical for liver surgery and partial liver transplantation: size or quality? Hepatology. 2010; 52:715–729.
32. Covey A.M., Brown K.T., Jarnagin W.R., et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008; 247:451–455.
33. Cummings L.C..,Payes J.D..,Coopers G.S. Survival of the hepatic resection in metastatic colorectal cancer.a population based study. Cancer. 2007; 109:718-726.
34. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360:1408–1417.
35. Day C.P., James O.F. Hepatic steatosis: innocent bystander or guilty party? Hepatology. 1998; 27,1463–1466.
36. Delaunoit T., Alberts S.R., Sargent D.J., et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol. 2005;16:425–429.
37. Deleve L.D., Wang X., Tsai J., et al. Sinusoidal obstruction syndrome (venoocclusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology. 2003;125:882–890.
38. Drixler T.A., Vogten M.J., Ritchie E.D., et al. Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg. 2002;.236:703–711; discuss ion 711–712.
39. Ducreux M., Ychou M., Laplanche A., et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationaledes Centres de Lutte Contre le Cancer. J Clin Oncol. 2005; 23(22):4881–4887.
40. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355:1041–1047.
41. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil,leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J ClinOncol. 2010; 28:4697–4705.
42. Elias D., Cavalcanti A., Sabourin J.C. et al. Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Sur Oncol. 1998;  69,88–93.
43. Elias D., Goere D., Boige V., et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol. 2007; 14:3188–3194.
44. Falcone A., Ricci S., Brunetti I., et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. JClin Oncol. 2007; 25:1670–1676.
45. Fernandez F.G., Drebin J.A., Linehan D.C., et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004; 240:438–447; discussion 447–450.
46. Feroci F., Fong Y. Use of clinical score to stage and predict outcome of hepatic resection of metastatic colorectal cancer. J Surg  Oncol. 2010; 102:914–921.
47. Figueras J., Torras J., Valls C., et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single center experience with 501 patients. Dis Colon Rect. 2007; 50: 478-488.
48. Floriani I., Torri V., Rulli E. et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J. Magn. Reson. Imaging. 2010; 31:19–31.
49. Folprecht G., Gruenberger T., Bechstein W.O. et al. Tumors response and secondary respectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomized phase 2 trial. Lancet Oncol. 2010; 11: 38-47.
50. Fong Y., Fortner J., Sun R.L. et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer, analysis of 1001 consecutive cases. Ann. Surg. 1999;230:309–321.
51. Fong Y., Bentrem D.J. CASH (Chemotherapy-Associated Steatohepatitis) costs. Ann Surg. 2006; 243:8–9.
52. Fornaro L., Masi G., Loupakis F., Vasile E., Falcone A. Palliative treatment of unresectable metastatic colorectal cancer. Expert Opin Pharmacother. 2010; 11,63–77.
53. Giacchetti S., Perpoint B., Zidani R., et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000; 18:136–147.
54. Giraudo G., Greget M., Oussoultzoglou E., et al. Preoperative contralateral portal vein embolization before major hepatic resection is a safe and efficient procedure: a large single institution experience. Surgery. 2008; 143:476–482.
55. Goere D., Farges O., Leporrier J., et al. Chemotherapy does not impair hypertrophy of the left liver after right portal vein obstruction. J Gastrointest Surg. 2006; 10:365–370.
56. Goere D., Deshaies I., de Baere T., et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010; 251:686–691.
57. Goshen E., Davidson T., Zwas S.T. et al. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol. Cancer Res. Treat 2006; 5:37–43.
58. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18:2938–2947.
59. Grand D.J., Beland M., Noto R.B., Mayo-Smith W. Optimum imaging of colorectal metastases. J  Surg  Oncol.2010; 102:909–913.
60. Grivicich I., Regner A., da Rocha A.B. et al. The irinotecan/5-fluorouracil combination induces apoptosis and enhances manganese superoxide dismutase activity in HT-29 human colon carcinoma cells. Chemotherapy. 2005;.51,93–102.
61. Gruenberger B., Tamandl D., Schueller J., et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008; 26:1830–1835.
62. de Haas R.J., Wicherts D.A., Adam R. Resection of colorectal liver metastases with extrahepatic disease. Dig  Surg 2008; 25:461– 466.
63. Hecht J.R , Mitchell E., Chidiac T., et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009; 27:672– 680.
64. Hagspiel K.D., Neidl K.F.W., Eicheberger A.C. et al. Detection of liver metastases: comparison of superparamagnetic iron oxide- enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US and percutaneous US. Radiology 1995; 196:471–478.
65. Hutchins G., Southward K., Handley K. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011; 29:1261–1270.
66. Jaeck D., Nakano H., Bachellier P. et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann Surg. Oncol . 2002; 9:430–438.
67. Jaeck D., Oussoultzoglou E., Rosso E., et al. A two-stage hepatectomy procedure co mbined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004; 240:1037–1049; discussion 1049–1051.
68. Iwatsuki S., Dvorcic I., Madariaga J.R., et al. Hepatic resecrion for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 159:291-299.
69. Kato T., Yasui K., Hirai T. et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis. Colon Rectum 2003; 46(Suppl. 10),S22–S31.
70. Kemeny N., Daly J., Reichman B., et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987; 107(4):459–465.
71. Kesmodel S.B., Ellis L.M., Lin E., et al. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008; 26:5254–5260.
72. Khatri V.P., Petrelli N.J., Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J  Clin  Oncol. 2005; 23:8490–8499.
73. Khatri V.P., Chee K.G., Petrelli N.J. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg  Oncol. 2007; 16:71–83.
74. Kingham T.P., D'Angelica M., Kemeny N.E. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancermetastases. J  Surg Oncol. 2010; 102:988–995.
75. Kishi Y., Zorzi D., Contreras C.M., et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010; 17:2870–6.
76. Kneuertz P.J., Maithel S.K., Staley C.A., Kooby D.A. Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases. Ann. Surg.  Oncol. 2011; 18:181–190.
77. Kopetz S., Chang G.J., Overman M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J. Clin. Oncol. 2009; 27:3677–3683.
78. Langer B., Bleiberg H., Labianca R., et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCICCTG/GIVIO) randomized trial. Proc. Am. Soc. Clin. Oncol. 2002; 21:149a (Abstract 592).
79. Loupakis F., Falcone A. Chemotherapy. How useful is adjuvant irinotecan in stage IV CRC? Nat  Rev Clin  Oncol. 2010; 7:190– 191.
80. Mahfud M., Breitenstein S., El-Badry A.M., et al. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg. 2010 ;34:92–100.
81. Mainenti P.P., Mancini M., Mainolfi C., et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom. . Imaging. 2010; 35:511–521.
82. Manfredi S., Lepage C., Hatem C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006; 244:254–259.
83. Masi G., Loupakis F., Pollina L., et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg, 2009; 249 : 420–425.
84. Masi G., Loupakis F., Salvatore L. et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a Phase 2trial. Lancet Oncol. 2010;11:845–852.
85. Mentha G., Terraz S., Morel P., et al. Dangerous halo after neoadjuvant chemotherapy and    two-step hepatectomy for colorectal liver metastases. Br J Surg. 2009; 96:95–103
86. Mocellin S., Pilati P., Lise M., et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007; 25:5649–5654.
87. Morris-Stiff G., Tan Y.M., Vauthey J.N. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol. 2008; 34:609–614.
88. Maughan T.S., Adams R., Smith C.G., et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. J Clin Oncol  (Meeting Abstracts). 2010; 28(15_suppl):3502.
89. Nakano H., Oussoultzoglou E., Rosso E., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008; 247:118–124.
90. Nash G.M., Gimbel M., Shia J. et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann. Surg. Oncol. 2010;17:572–578.
91. Niekel M.C., Bipat S., Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment..Radiology 2010; 257:674–684.
92. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371 (9617):1007–1016.
93. Oussoultzoglou E., Romain B., Panaro F., et al. Long-term survival after liver resection for colorectal liver metastases inpatients with hepatic pedicle lymph nodes involvement in the era of new chemotherapy regimens. Ann Surg. 2009; 249:879–886.
94. Overman M.J., Maru D.M., Charnsangavej C., et al. Oxaliplatin-mediated increase in Spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010; 28:2549–2555.
95. Patel S., McCall M., Ohinmaa A. et al. Positron emission tomography/computed Tomography scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg. 2011; 253:666–671.
96. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastase Ann Surg. 2005;241: 715–722, discussion 722–724.
97. Pawlik T.M., Olino K., Gleisner A.L. et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatichistology and postoperative outcome. J Gastrointest Surg. 2007;11:860–868.
98. Pawlik T.M., Assumpcao L., Vossen J.A. et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases timothy. Ann Surg Oncol. 2009;16:371–378.
99. Piessevaux H. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer (MCRC): Analysis from the CRYSTAL study. ESMO abstract 596P. 2010.
100. Portier G., Elias D., Bouche O., et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases:FFCD ACHBTH AURC 9002 trial. J Clin Oncol.2006; 24:4976–4982.
101. Power D.G., Kemeny N.E. Role of adjuvant therapy after resection of colorectal cancer Liver metastases. J. Clin.Oncol. 2010; 28:2300–2309.
102. Quaia E., D'Onofrio M., Palumob A. et al. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol. 2006; 16:1599–1609.
103. Reddy S.K., Morse M.A., Hurwitz H.I., et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg. 2008; 206:96–106.
104. Reddy S.K., Zorzi D., Lum Y.W., et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16:1809–1819.
105. Rees M., Tekkis P.P., Welsh F.K., et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008; 24:125–135.
106. Reissfelder C., Rahbari N.N., Koch M. et al. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009; 16:3279–3288.
107. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007; 110:2761–2767.
108. Richman S.D., Seymour M.T., Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009; 27:5931–5937.
109. Rojas Llimpe F., Di Fabio F., Ercolani G., et al. Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study). Presented at: 2009 ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June2009.
110. De Roock W., Jonker D.J., Di Nicolantonio F., et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010; 304:1812–1820.
111. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- Refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010; 11:753–762.
112. Roth A.D., Tejpar S., Delorenzi M. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010; 28:466–474.
113. Rubbia-Brandt L., Audard V., Sartoretti P., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466.
114. Rubbia-Brandt L., Lauwers G.Y., Wang H., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology. 2010; 56:430–439.
115. Ryan P., Nanji S., Pollett A., et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol. 2010; 34:784–791.
116. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000; 343:905–914.
117. Saltz L.B., Clarke S., Diaz-Rubio E., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26:2013–2019.
118. Sahani D.V., Kalva S.P., Tanabe K.K., et al. Intraoperative US in patients undergoing surgery for liver neoplasms: comparison with MR imaging. Radiology 2004; 232:810–814.
119. de Santibañes E., Fernandez D., Vaccaro C., et al. Short-term and long-term outcomes after simultaneous resection of colorectal malignancies and synchronous liver metastases. World J Surg. 2010; 34:2133–2140.
120. Scappaticci F.A., Fehrenbacher L., Cartwright T., et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91:173–180.
121. Selzner N., Pestalozzi B.C., Kadry Z., et al. Downstaging colorectal liver metastases by concomitant unilateral portal vein ligation and selective intra-arterial chemotherapy. Br J Surg. 2006; 93:587–592.
122. Soubrane O., Brouquet A., Zalinski S., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg.2010; 251:454–460.
123. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer. Biologic perspective. Ann Surg. 1989; 210:127–138.
124. Strasberg S.M., Dehdashti F. Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer. J. Surg. Oncol. 2010; 102:955–959.
125. Tabernero J., Van Cutsem E., Diaz-Rubio E., et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007; 25:5225–5232.
126. Takamoto T., Hashimoto T., Sano K., et al. Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis. Ann Surg Oncol. 2010; 17:2747–2755.
127. Tan M.C., Linehan D.C., Hawkins W.G. et al. Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointes Surg. 2007; 11:1112–1119.
128. Tamandl D, Gruenberger B, Klinger M, et al. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Ann Surg. 2010; 252:124–130.
129. Tanaka K., Shimada H., Ueda M., et al. Perioperative complications after hepatectomy with or without intra-arterial chemotherapy for bilobar colorectal cancer liver metastases. Surgery. 2006; 139:599–607.
130. Taniguchi E., Sakisaka S., Matsuo K., et al. Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem. 2001; 49:121–130.
131. Taylor I. Adjuvant chemotherapy after resection of liver metastases from colorectal cancer. Eur. J. Cancer 2008; 44,1198–1201.
132. Teli M.R., James O.F., Burt A.D. et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995; 22:1714–1719.
133. Tie J., Lipton L., Desai J. et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin. Cancer Res. 2011; 17:1122–1130.
134. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009; 360:563–572.
135. Tomlinson J.S., Jarnagin W.R., DeMatteo R.P. et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol. 2007; 25:4575–4580.
136. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24:2065–2072.
137. Vauthey J.N., Choti M.A., Helton W.S. AHPBA/SSO/SSAT consensus conference on hepatic colorectal metastases: rationale and overview of the conference. Ann Surg Oncol. 2006; 13:1259–1260.
138. Weber S.M., Jarnagin W.R., DeMatteo R.P., et al. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000; 7:643–650.
139. Welsh F.K., Tilney H.S., Tekkis P.P., et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007; 96:1037–1042.
140. Wernecke K., Rummeny E., Bongartz G., et al. Detection of hepatic masses in patients with carcinoma: comparative sensitivities of sonography, CT, and MR imaging. Am. J. Roentgenol.1991; 157:731–739.
141. Wildi S.M., Gubler C., Hany T., et al. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound. 2008; 36:20–26.
142. Wilson S.R., Greenbaum L.D., Goldberg B.B. Contrast-enhanced ultrasound: what is the evidence and what are the obstacles? Am J Roentgenol. 2009; 193:55–60.
143. Ychou M., Hohenberger W., Thezenas S., et al. A randomized Phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 2009; 20:1964–1970.
144. Zorzi D., Laurent A., Pawlik T.M., et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007; 94:274–286.
145. Zorzi D., Chun Y.S., Madoff D.C., et al. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008; 15:2765–2772.